As the binding of PD-L1 to PD-1 or CD-80 inhibits the activation of T-lymphocytes, this blockade impairs the tumor immune system evasion by allowing T-cell responses to occur, thus enhancing anti-tumor activity [50]. This evidence concerns the gene CD274 and neoplasm.